Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17512408 | 0.96 | MAPT (0.51) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL19033237 | 0.92 | MAPT (0.48) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL7150141 | 0.86 | MEN1 (0.57) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL17512405 | 0.82 | TSHR (0.56) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL17512436 | 0.81 | MAPT (0.53) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL17512428 | 0.81 | TSHR (0.59) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL17512370 | 0.80 | NPC1 (0.54) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL7149932 | 0.80 | CPT2 (0.64) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL22966721 | 0.78 | MAPT (0.61) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL19034468 | 0.78 | NPC1 (0.61) | MAPTNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688637-B2 | 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members | NORTHWESTERN UNIVERSTIY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688637-B2 | 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members | NORTHWESTERN UNIVERSTIY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688637-B2 | 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members | NORTHWESTERN UNIVERSTIY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160052870-A1 | 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G AND OTHER A3 FAMILY MEMBERS | NORTHWESTERN UNIVERSITY (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2016029136-A1 | 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G | NORTHWESTERN UNIVERSITY (US) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052870-A1 | 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G AND OTHER A3 FAMILY MEMBERS | L3MBTL3, AFG3L2, AMPD3 | MAPT 4742/4885NPC1 2573/4885RAB9A 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.